Among the most widely administered MDS treatment approaches, AZA and DAC, are considered inhibitors of DNMT1, which is almost completely depleted after HMA exposure, whereas DNMT3A is significantly less sensitive and DNMT3B seems completely resistant to HMAs [19]. The gene discussed is DNMT3B; the disease is myelodysplastic syndrome.